Skip to main
HIMS

HIMS Stock Forecast & Price Target

HIMS Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 23%
Buy 15%
Hold 62%
Sell 0%
Strong Sell 0%

Bulls say

Hims & Hers Health is poised for long-term growth due to its convenient and personalized healthcare offerings, as well as its partnership with Novo Nordisk. While the company has faced some challenges, such as a recent earnings miss and competition in the market, their focus on expanding into new market segments and addressing legal concerns sets them up for potential success in the future. With a strong subscriber base and a solid business model, Hims & Hers has the potential to be a strong player in the telehealth industry.

Bears say

Hims & Hers Health is a telehealth platform with a negative outlook due to its declining average monthly revenue per subscriber, increasing competition from both established healthcare giants and nimble, venture-backed startups, and potential risks to its compounding business from tighter regulations. While the company has more than 2 million subscribers and is expanding globally, it faces challenges in maintaining durable unit economics and high marketing yields to sustain its DTC business model. Furthermore, its entrance into the GLP-1 market poses considerable risks due to heightened scrutiny from drug companies and potential regulatory challenges. While management remains bullish on the company's growth potential and has raised revenue guidance for fiscal year 2026, there are concerns about profitability and sustainability in the highly competitive telehealth industry.

HIMS has been analyzed by 13 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 15% recommend Buy, 62% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hims & Hers Health (HIMS) Forecast

Analysts have given HIMS a Buy based on their latest research and market trends.

According to 13 analysts, HIMS has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hims & Hers Health (HIMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.